Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

I see that Novo Nordisk is cheaper than its main competitor ... clear signs of a turnaround in investor sentiment. Don't get me wrong. In the long term, I believe the company is a solid buy.

The future of GLP-1 drugs is looking bigger than anyone predicted. As governments consider broader adoption and competitors scramble to keep up, Novo Nordisk is well-positioned to lead this ...

Novo Nordisk A/S’s blockbuster drug Wegovy was ... 17.5% reduction among people who got a standard dose — but was less than either the highest dose of Eli Lilly & Co.’s Zepbound or the ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab ... Novo believes CagriSema could be more powerful than its blockbuster weight-loss injection Wegovy, but investors ...